PerkinElmer
check quantity

Neutrophil Elastase 680 FAST Fluorescent Imaging Agent

Near-infrared (NIR) fluorescent agent for in vivo imaging and other applications. 

For laboratory use only. This product is intended for animal research only and not for use in humans.

Part Number
List Price
Your Price
Quantity
NEV11169
710.00 USD
 
more
Buy Now

Please enter valid quantity

Please log in to add favorites.

NULL OR EMPTY CART

Overview

Neutrophil Elastase 680 FAST™ is a member of a family of activatable fluorescent imaging agents comprising a novel architecture, termed F.A.S.T. (Fluorescent Activatable Sensor Technology) that confers an improved pharmacokinetic profile with a broader range of early imaging time points. This architecture also offers higher target specific signal with reduced background. 

Neutrophil Elastase 680 FAST is a neutrophil elastase activatable agent that is optically silent upon injection and produces fluorescent signal after cleavage by elastase produced by neutrophil cells. Neutrophil elastase is a key protease involved in acute lung injury, acute respiratory distress syndrome, as well as many other inflammatory processes such as emphysema, cystic fibrosis, COPD, wound healing, rheumatoid arthritis, ischemia-reperfusion and many others. 

Neutrophil Elastase 680 FAST fluorescent imaging agent is a selective neutrophil elastase-activatable agent designed for imaging of this serine protease both in vitro and in vivo. The half-life in plasma of Neutrophil Elastase 680 FAST is 4 hours.

Specifications

Fluorescent Agent Type Activatable
Optical Imaging Classification Fluorescence Imaging
Quantity in a Package Amount 1.0 Units
Shipping Condition Blue Ice
Therapeutic Area Inflammation
Unit Size 1 Vial (10 doses)
Wave Length 680 nm
Resources, Events & More
  • All

Ebook

In Vivo Imaging Solutions eBook

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.

PDF 4 MB

Flyer

Poster

A novel NIR dye for in vivo temporal tracking of labeled macrophages to sites of acute inflammation

A novel NIR dye for in vivo temporal tracking of labeled macrophages to sites of acute inflammation

PDF 689 KB
Non-Invasive Quantitative Tomography of Disease Progression and Therapeutic Response

We have demonstrated the ability of our Fluorescence Tomography (FMT 2500) in vivo imaging system and ProSense 680 to non-invasively visualize and quantify inflammation in the lung in a robust and validated manner. The consistency of the quantitative tomography, as well as its excellent correlation with BAL assessment of eosinophilia, provide a powerful toolkit for quantifying the therapeutic efficacy of dexamethasone treatment. Utilizing new and existing imaging agents, FMT imaging in asthma research provides useful, non-invasive tools for understanding pulmonary inflammation and for developing new therapeutics in vivo.

PDF 581 KB

Technical Note

Neutrophil Elastase 680 FAST (Protocol)

Neutrophil Elastase 680 FAST activatable fluorescent imaging agent Protocol

PDF 257 KB
Neutrophil Elastase 680 FAST™ (Data Sheet)

Neutrophil Elastase 680 FAST™ is a member of a family of activatable fluorescent imaging agents comprising a novel architecture, termed F.A.S.T. (Fluorescent Activatable Sensor Technology) that confers an improved pharmacokinetic profile with a broader range of early imaging time points. This architecture also offers higher target specific signal with reduced background.

PDF 68 KB

White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 748 KB